| Management target | Revenue 18.0% FY27 |
|---|
| Revenue growth | 9% YoY growth to ₹82 Cr, organic growth accelerating. |
|---|---|
| Margins | EBITDA margins expanded by 240 bps to 23% plus. |
| Demand visibility | Strong visibility in Gynaecology, Ortho, and Dermatology segments. |
| Management confidence | High confidence in 1.5x industry growth rate targets. |
Growth
Revenue grew 9% YoY to ₹82 Cr, while EBITDA and Net Profit grew 21% and 22% respectively.
Outlook
Equitas is expected to hit ₹100 Cr revenue and ₹10 Cr EBITDA by Year 2 post-integration.
Risks
High concentration in the 'Maintain' brand and historically longer working capital cycles in the hospital segment.
Last quarter's promises, checked
Delivered
- Guided double-digit growth → delivered 14.2% in Q4 (MAT 12.2%) (= BEAT)
- Guided 1.5x IPM growth → delivered 14.2% vs 10.5% industry (= BEAT)
- Guided 19% PAT growth → delivered 19% profit growth (= BEAT)
Earnings Call Transcript filed with NSE, NSE: JAGSNPHARM. Summary written with AI assistance from the document.
Jagsonpal Pharmaceuticals Ltd: key numbers
- Share price
- ₹236.58
- Market cap
- ₹1,560 Cr
- Revenue (annual)
- ₹287.2 Cr
- Net profit (annual)
- ₹43.08 Cr
- P/E (TTM)
- 34.3×Sector 47.4×
- Promoter holding
- 69.05%+1.16% QoQ
- FII holding
- 2.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jagsonpal Pharmaceuticals Ltd
All →Jagsonpal Pharmaceuticals Acquisition Worth ₹46.7 Cr
Jagsonpal Pharmaceuticals Ltd will acquire the Wellness Portfolio of Group Pharmaceuticals Ltd. The transaction involves a total consideration capped at ₹46.7 Crore.
- Value
- ₹46.70 Cr
Jagsonpal Pharmaceuticals Annual General Meeting
Jagsonpal Pharmaceuticals held its 47th Annual General Meeting on September 18, 2026. Shareholders transacted business including adoption of financial statements and director appointments.
Jagsonpal Pharmaceuticals Business Update
Jagsonpal Pharmaceuticals Ltd has filed its Business Responsibility and Sustainability Report for the financial year 2025-26. This report forms part of its annual report.
Jagsonpal Pharmaceuticals Annual General Meeting
Jagsonpal Pharmaceuticals Ltd has issued the notice for its 47th Annual General Meeting, scheduled for September 18, 2026, alongside the Annual Report for FY 2025-26.
Jagsonpal Pharmaceuticals Other Announcement
The company informed shareholders without registered email addresses of the web-link to access the 2025-26 Annual Report and AGM Notice, per Regulation 36(1)(b).
Jagsonpal Pharmaceuticals Employee Stock Options
Jagsonpal Pharmaceuticals Limited allotted 27,950 equity shares following the exercise of employee stock options. This increases the company's total paid-up share capital to Rs. 13.19 Crore.